Grants & Contracts

2016

Fitzpatrick LR. NIH Phase 2 SBIR grant to Visionary Pharmaceuticals. PI on subcontract ($5,995). Colonic Histology Evaluations Related to the Effects of ROR-γ T Inhibitors on Mice with Innate Immune Colitis. (Award occurred in February of 2016).  

Fitzpatrick LR. NIH Phase 2 SBIR grant to Visionary Pharmaceuticals. PI on subcontract ($15,455). Ex Vivo Evaluations with Visionary ROR-Gamma T Inhibitors Using a Murine Model of Inflammatory Bowel Disease. (Award occurred in July of 2016).

Phuong O. Merck Sharp & Dohme CORE proposal ($20,000). PI: Hospitalization for Heart Failure (HHF) Risks of Various DPP-4 Inhibitors. (Submitted in March of 2016). 

Vinall R. NIH R15 ($300,000 direct costs). PI: Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities. Grant was submitted in 2015. (Award occurred in July of 2016)


Vinall R. NIH P20 ($708,932). PI: 1/2 Pharmacists and Cancer researchers Together: the CNUCOP-UCDCCC PACT. (Submitted in March of 2016).

California Northstate University College of Pharmacy ♦ 9700 West Taron Drive ♦ Elk Grove, CA 95757 ♦ Phone: (916) 686-7400